Tumor-associated MICA is shed by ADAM proteases - PubMed (original) (raw)
Tumor-associated MICA is shed by ADAM proteases
Inja Waldhauer et al. Cancer Res. 2008.
Abstract
The immunoreceptor NKG2D promotes immunosurveillance of malignant cells and protects the host from tumor initiation by activating natural killer cells and costimulating CD8 T cells. NKG2D-mediated recognition of malignant cells by cytotoxic lymphocytes is enabled through the tumor-associated expression of NKG2D ligands (NKG2DL) resulting from cellular or genotoxic stress. Shedding of NKG2DL is thought to constitute a major countermechanism of tumor cells to subvert NKG2D-mediated immunosurveillance. Here, we report that the prototypical NKG2DL MICA is released by proteolytic cleavage in the stalk of the MICA ectodomain, where deletions, but not alanine substitutions, impede MICA shedding. Small compound-mediated stimulation and inhibition of MICA shedding adduced characteristics that indicated an involvement of members of the "a disintegrin and metalloproteinase" (ADAM) family. Accordingly, MICA shedding by tumor cells was inhibited by silencing of the related ADAM10 and ADAM17 proteases, which are known to promote tumor growth by releasing epidermal growth factor receptor ligands. Collectively, our data show that ADAM10 and ADAM17 are critically involved in the tumor-associated proteolytic release of soluble MICA facilitating tumor immune escape. Hence, therapeutic blockade of ADAM10 and ADAM17 seems promising for cancer treatment by targeting both growth and immune escape of tumors.
Similar articles
- Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
Chitadze G, Lettau M, Bhat J, Wesch D, Steinle A, Fürst D, Mytilineos J, Kalthoff H, Janssen O, Oberg HH, Kabelitz D. Chitadze G, et al. Int J Cancer. 2013 Oct 1;133(7):1557-66. doi: 10.1002/ijc.28174. Epub 2013 Apr 18. Int J Cancer. 2013. PMID: 23526433 - Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
Waldhauer I, Steinle A. Waldhauer I, et al. Cancer Res. 2006 Mar 1;66(5):2520-6. doi: 10.1158/0008-5472.CAN-05-2520. Cancer Res. 2006. PMID: 16510567 - Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.
Kohga K, Takehara T, Tatsumi T, Miyagi T, Ishida H, Ohkawa K, Kanto T, Hiramatsu N, Hayashi N. Kohga K, et al. Cancer Res. 2009 Oct 15;69(20):8050-7. doi: 10.1158/0008-5472.CAN-09-0789. Epub 2009 Oct 13. Cancer Res. 2009. PMID: 19826051 - How to exploit stress-related immunity against Hodgkin's lymphoma: Targeting ERp5 and ADAM sheddases.
Poggi A, Zocchi MR. Poggi A, et al. Oncoimmunology. 2013 Dec 1;2(12):e27089. doi: 10.4161/onci.27089. Epub 2013 Dec 5. Oncoimmunology. 2013. PMID: 24498565 Free PMC article. Review. - The NKG2D axis: an emerging target in cancer immunotherapy.
Lazarova M, Steinle A. Lazarova M, et al. Expert Opin Ther Targets. 2019 Apr;23(4):281-294. doi: 10.1080/14728222.2019.1580693. Epub 2019 Feb 22. Expert Opin Ther Targets. 2019. PMID: 30732494 Review.
Cited by
- MHC class I polypeptide-related sequence B shedding modulates pancreatic tumor immunity via the activation of NKG2DLow T cells.
Toyoda H, Kuramasu A, Hosonuma M, Murayama M, Narikawa Y, Isobe J, Baba Y, Tajima K, Funayama E, Shida M, Maruyama Y, Sasaki A, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Kobayashi S, Horiike A, Hida N, Sambe T, Nobe K, Wada S, Kobayashi H, Tsuji M, Kobayashi S, Tsunoda T, Kudo Y, Kiuchi Y, Yoshimura K. Toyoda H, et al. Sci Rep. 2024 Oct 8;14(1):23401. doi: 10.1038/s41598-024-73712-1. Sci Rep. 2024. PMID: 39379424 Free PMC article. - Unraveling the role of ADAMs in clinical heterogeneity and the immune microenvironment of hepatocellular carcinoma: insights from single-cell, spatial transcriptomics, and bulk RNA sequencing.
Chen J, Yuan Q, Guan H, Cui Y, Fu C, Wei T, Liu K. Chen J, et al. Front Immunol. 2024 Sep 13;15:1461424. doi: 10.3389/fimmu.2024.1461424. eCollection 2024. Front Immunol. 2024. PMID: 39346916 Free PMC article. - Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia.
Leifheit ME, Johnson G, Kuzel TM, Schneider JR, Barker E, Yun HD, Ustun C, Goldufsky JW, Gupta K, Marzo AL. Leifheit ME, et al. Int J Mol Sci. 2024 Aug 30;25(17):9448. doi: 10.3390/ijms25179448. Int J Mol Sci. 2024. PMID: 39273395 Free PMC article. Review. - A potential mechanism of tumor immune escape: Regulation and application of soluble natural killer group 2 member D ligands (Review).
Huang S, Qin Z, Wang F, Kang Y, Ren B. Huang S, et al. Oncol Rep. 2024 Oct;52(4):137. doi: 10.3892/or.2024.8796. Epub 2024 Aug 19. Oncol Rep. 2024. PMID: 39155864 Free PMC article. Review. - Nanobody-based CAR NK cells for possible immunotherapy of MICA+ tumors.
Verhaar ER, van Keizerswaard WJC, Knoflook A, Balligand T, Ploegh HL. Verhaar ER, et al. PNAS Nexus. 2024 May 6;3(5):pgae184. doi: 10.1093/pnasnexus/pgae184. eCollection 2024 May. PNAS Nexus. 2024. PMID: 38756234 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous